Intercept Boosts NASH Commercial Potential Via NICE Rare Disease Move
With Gilead snapping at its heels in NASH, Intercept will be pleased with its product's positive reimbursement recommendation in the UK for rare disease PBC; physicians will have the opportunity to familiarize themselves with Intercept's offering.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Novartis is teaming up with Allergan in a bid to get a treatment on the market for the fatty liver disease NASH, which currently has no approved treatments. The decision by Novartis to test its lead FXR agonist with Allergan's cenicriviroc (CVC) is interesting because Allergan's product reported mixed Phase II data.
Ocaliva could now qualify for accelerated approval in NASH by meeting either of two Phase III co-primary endpoints, whereas the trial initially was designed for success on both measures.